2026 Global: Coronary Stents Market -Competitive Review (2032) report
Description
The 2026 Global: Coronary Stents Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for coronary stents market by geography and historical trend. The scope of the report extends to sizing of the coronary stents market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Medtronic, Abbott, Boston Scientific, B. Braun, Terumo, Biotronik, MicroPort, Lepu, Meril Life Sciences, and Biosensors International are widely recognised among the ten major companies competing in the global coronary stents market. Medtronic is a long-established global medical device leader with broad cardiovascular capabilities and sustained R&D investment that support an extensive portfolio of coronary and peripheral stents across multiple material and drug-eluting platforms. Abbott is a market-leading developer of drug‑eluting stents (including Xience), carotid and peripheral stent systems and benefits from deep clinical evidence and wide commercial penetration in both developed and emerging markets. Boston Scientific holds a leading position in drug‑eluting stents with established product lines such as Synergy and other DES platforms, and it is frequently cited as one of the top competitors in market share analyses for coronary stents. B. Braun, a major European medtech group, contributes to the competitive landscape through its vascular intervention products and established distribution channels across Europe and global markets. Terumo, headquartered in Japan, leverages strong interventional cardiology heritage and catheter technologies to deliver complementary coronary stent and ancillary device portfolios that support procedural adoption in Asia Pacific and other regions. Biotronik offers a range of coronary stents and specialty scaffolds with emphasis on proprietary alloys and digital follow‑up solutions; the company’s devices and recent corporate transactions have influenced availability of drug‑coated balloons and resorbable scaffold technology across portfolios. MicroPort, a major Chinese manufacturer, has scaled rapidly and announced multi‑million unit milestones for coronary stent shipments and implantations, reflecting strong domestic volume growth and accelerating international expansion of DES and next‑generation platforms. Lepu Medical, another China‑based competitor, competes on price and local procurement channels in Asian public tender markets, enabling rapid unit growth and regional market share gains alongside technology iterations. Meril Life Sciences, from India, and Biosensors International (Singapore) are regionally significant players that supply cost‑competitive DES, bioresorbable scaffolds and niche platforms for emerging markets while pursuing clinical data to support wider adoption. Collectively these ten firms shape the market through differentiated strategies: global incumbents (Medtronic, Abbott, Boston Scientific) focus on incremental clinical outcomes, premium DES chemistry and broad commercial networks; large diversified groups (B. Braun, Terumo, Biotronik) leverage adjacent product lines and regional strengths; and emerging manufacturers (MicroPort, Lepu, Meril, Biosensors) combine aggressive pricing, local tender access and rapid iteration on thin‑strut DES and scaffold technologies to expand share. Recent industry activity illustrating these dynamics includes consolidation and technology acquisitions that integrate intravascular lithotripsy, drug‑coated balloons, and resorbable scaffolds into broader coronary portfolios, while market reports consistently rank Boston Scientific, Medtronic and Abbott among the top three by share, with sizeable contributions from the other seven firms across different regions and product segments.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for coronary stents market by geography and historical trend. The scope of the report extends to sizing of the coronary stents market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Medtronic, Abbott, Boston Scientific, B. Braun, Terumo, Biotronik, MicroPort, Lepu, Meril Life Sciences, and Biosensors International are widely recognised among the ten major companies competing in the global coronary stents market. Medtronic is a long-established global medical device leader with broad cardiovascular capabilities and sustained R&D investment that support an extensive portfolio of coronary and peripheral stents across multiple material and drug-eluting platforms. Abbott is a market-leading developer of drug‑eluting stents (including Xience), carotid and peripheral stent systems and benefits from deep clinical evidence and wide commercial penetration in both developed and emerging markets. Boston Scientific holds a leading position in drug‑eluting stents with established product lines such as Synergy and other DES platforms, and it is frequently cited as one of the top competitors in market share analyses for coronary stents. B. Braun, a major European medtech group, contributes to the competitive landscape through its vascular intervention products and established distribution channels across Europe and global markets. Terumo, headquartered in Japan, leverages strong interventional cardiology heritage and catheter technologies to deliver complementary coronary stent and ancillary device portfolios that support procedural adoption in Asia Pacific and other regions. Biotronik offers a range of coronary stents and specialty scaffolds with emphasis on proprietary alloys and digital follow‑up solutions; the company’s devices and recent corporate transactions have influenced availability of drug‑coated balloons and resorbable scaffold technology across portfolios. MicroPort, a major Chinese manufacturer, has scaled rapidly and announced multi‑million unit milestones for coronary stent shipments and implantations, reflecting strong domestic volume growth and accelerating international expansion of DES and next‑generation platforms. Lepu Medical, another China‑based competitor, competes on price and local procurement channels in Asian public tender markets, enabling rapid unit growth and regional market share gains alongside technology iterations. Meril Life Sciences, from India, and Biosensors International (Singapore) are regionally significant players that supply cost‑competitive DES, bioresorbable scaffolds and niche platforms for emerging markets while pursuing clinical data to support wider adoption. Collectively these ten firms shape the market through differentiated strategies: global incumbents (Medtronic, Abbott, Boston Scientific) focus on incremental clinical outcomes, premium DES chemistry and broad commercial networks; large diversified groups (B. Braun, Terumo, Biotronik) leverage adjacent product lines and regional strengths; and emerging manufacturers (MicroPort, Lepu, Meril, Biosensors) combine aggressive pricing, local tender access and rapid iteration on thin‑strut DES and scaffold technologies to expand share. Recent industry activity illustrating these dynamics includes consolidation and technology acquisitions that integrate intravascular lithotripsy, drug‑coated balloons, and resorbable scaffolds into broader coronary portfolios, while market reports consistently rank Boston Scientific, Medtronic and Abbott among the top three by share, with sizeable contributions from the other seven firms across different regions and product segments.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.